ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Thursday, 22 May 2014

Bulgaria Pharmaceutical Market include new market research report" The Pharmaceutical Market: Bulgaria" to its huge collection of research reports.


The Bulgarian government is planning to earmark some BGN150-160mn (US$98.65-105.23mn) in additional funding for healthcare in 2013, the government's press service cited Prime Minister Boyko Borisov as saying in October 2012 . The funds are expected to be used to purchase new equipment, upgrade hospitals and general ly improve Bulgarian health services. We have long highlighted the likelihood of increased public spending ahead of the 2013 parliamentary election, although we do not foresee significant risks to fiscal sustainability , given that Bulgaria has the second lowest public d ebt load in the European Union - at 17.5% of GDP (end-2011).

However, as BMI has been warning since February 2012, the government has pushed ahead with changes to Bulgaria's pricing and reimbursement regime. For example, the external reference pricing mechanism for pharmaceuticals, which now takes into account 12 countries - up from eight previously - is expected to have a negative effect on the prices of a number of medicines listed for reimbursement.

Headline Expenditure Projections

Pharmaceuticals: BGN2.10bn (US$1.49bn) in 2011 to BGN2.23bn (US$1.44bn) in 2012; +6.1% in local currency terms and -3.3% in US dollar terms. Forecast unchanged since Q412.

Healthcare: BGN5.12bn (US$3.64bn) in 2011 to BGN5.22bn (US$3.38bn) in 2012; +1.9% in local currency terms and -7.1% in US dollar terms. Forecast unchanged since Q412.

MedicalDevices: BGN281mn (US$200mn) in 2011 to BGN285mn (US$185mn) in 2012; +1.7% in local currency terms and -7.4% in US dollar terms. Forecast unchanged since Q412.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

All Latest Market Research Report @

For More Information Kindly Contact:


Post a Comment